Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors (Q66078946)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors |
clinical trial |
Statements
A Phase 1 Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors (English)
0 references
28 November 2016
0 references
30 June 2020
0 references
45
0 references
20 year
0 references